Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor

Name: Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor
License: Public Domain

National Cancer Institute (NCI)

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

metastatic lung non-small cell carcinoma, recurrent lung non-small cell carcinoma, stage iv lung cancer ajcc v8

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 454015
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.